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Abstract Speciﬁc mutations in BRCA1 and BRCA2
genes have been identiﬁed in speciﬁc populations and
ethnic groups. However, little is known about the con-
tribution of BRCA1 and BRCA2 mutations to breast
cancers in the Indonesian population. One hundred-
twenty moderate to high risk breast cancer patients
were tested using PCR-DGGE, and any aberrant band
was sequenced. Multiplex ligation-dependent probe
ampliﬁcation (MLPA) was performed on all samples to
detect large deletions in the two genes. Twenty-three
different mutations were detected in 30 individuals, ten
were deleterious mutations and 20 were ‘‘unclassiﬁed
variants’’ with uncertain clinical consequences. Three
of seven (c.2784_2875insT, p.Leu1415X and del exon
13–15) and two of four (p.Glu2183X and p.Gln2894X)
deleterious mutations that were found in BRCA1 and
BRCA2 respectively, are novel. Several novel, patho-
genic BRCA1 and BRCA2 germline mutations are
found in early onset Indonesian breast cancer patients,
these may therefore be speciﬁc for the Indonesian
population.
Keywords BRCA1  BRCA2  Hereditary breast
cancer  Mutation analysis
Introduction
Breast cancer is the most common cancer in women. In
5% to 10% of breast cancer cases, the disease results
from a hereditary predisposition [1, 2], which can to a
large extent be attributed to mutations in either of two
tumour suppressor genes, BRCA1 (MIM# 113705) and
BRCA2 (MIM# 600185) [3–5]. These genes are in-
volved in DNA repair as well as transcriptional regu-
lation [6, 7]. Women carrying pathogenic germline
mutations in either of these genes tend to develop
breast cancer at an early age [8, 9].
The BRCA1 and BRCA2 genes encode large pro-
teins of 1,863 and 3,418 amino acids, respectively. Over
300 distinct mutations in BRCA1 and BRCA2 have
been described [10, 11]. These mutations are widely
scattered across both genes and most affect the struc-
ture and function of the gene. Nevertheless, a signiﬁ-
cant proportion (34% of BRCA1 and 38% of BRCA2
mutations) (http://www.nhgri.nih.gov/Intramural_resea
rch/Lab_transfer/Bic) are missense mutations that alter
one amino acid, but do not truncate the protein and
are rare sequence variants of unknown functional
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DOI 10.1007/s10549-006-9493-4consequence. Moreover, a number of base substitu-
tions do not alter the amino acid sequence or result in
amino acid changes not associated with disease (poly-
morphisms) [12]. Hence the biggest challenge in
interpreting the mutation analysis of BRCA1 and
BRCA2 genes is to distinguish between harmless
polymorphisms and deleterious mutations associated
with increased cancer risk.
Inaddition,mutationsspeciﬁcforcertainpopulations
and ethnic groups have been identiﬁed in both genes.
For example, speciﬁc BRCA1 and BRCA2 mutations
were reported for Ashkenazi Jews [13]. Other common
BRCA1 mutations were especially found in Italian,
Canadian, Belgian or Dutch breast cancer families [14–
16]. In Indonesia, the contribution of the BRCA1/
BRCA2 mutations to the population incidence of early-
onset breast cancer is largely unknown. In one pilot
study, however, a new BRCA2 mutation was identiﬁed
[17] indicating that it was worthwhile to more exten-
sively study the Indonesian population, which was the
aim of this study. The accumulating knowledge about
the prevalence and nature of BRCA1 and BRCA2
mutations in speciﬁc populations may facilitate the
interpretation of genetic analysis with regard to breast
cancer risk of individual patients.
Materials and methods
Patients
A total of 120 unrelated breast cancer patients and 16
of their family members from three Indonesian cities
(Jakarta and Jogjakarta on the Java island, Denpasar
on the Bali island) were analyzed. Breast cancer pa-
tients at moderate to high-risk of a hereditary predis-
position were selected according to the following
criteria: (A) Breast cancer before the age of 41
(n = 102); (B) Two cases of breast cancer in the same
family before the age of 60 (n = 9); (C) Three or more
cases of breast cancer in the same family (n = 2); (D)
Bilateral breast cancer (n = 7). Subjects were asked to
ﬁll out questionnaires to evaluate their personal and
family histories, and blood specimens were collected
for determination of BRCA mutations. Informed
consent was obtained from all the subjects in this study.
DNA extraction and PCR ampliﬁcation
Genomic DNA was isolated by the saturated salt
extraction procedure as described in [18]. All 22 coding
exons of BRCA1 and 26 coding exons of BRCA2 were
ampliﬁed using primer sequences developed by the
University of Groningen, The Netherlands [19]. Prim-
ers for DGGE were obtained from Ingeny (Goes, The
Netherlands). Genomic DNA was ampliﬁed using 100–
200 ng of template DNA, 10 pmol of the mixture of 40-
mer primers, 30 mM of MgCl, 3 mM dNTPs (Invitro-
gen) and 0.7 unit of Platinum Taq (Invitrogen) in 9 ll
PCR reactions. In order to speed up the test, the PCR
reaction was placed in 384 well plates using a pipetting
robot (TECAN Miniprep 75). PCR conditions were
performed as previously described [17].
Denaturing Gradient Gel Electrophoresis and
DNA sequencing
A 4–6 ll aliquot of each PCR product with relatively
large melting temperature differences were pooled as
previously described [17] with some modiﬁcations for
optimal results. The fragment pool was designed based
on melting proﬁles and sequence. Electrophoresis was
performed in 0.5 TAE buffer at 58 C, 120 V for 16 h
for BRCA1 gene, and 55 C, 100 V for 18 h for
BRCA2. Gels were stained with ethidium bromide and
photographed under a UV transilluminator. The
aberrantly migrating samples were re-ampliﬁed using
sequencing primers and sequencing was performed
using Big Dye Cycle-sequencing kit according to the
manufacturer’s instructions. The reaction products
were analyzed using an ABI 3100 DNA Sequencer
(Applied Biosystems, Torrence, CA, USA) and se-
quence ﬁles were edited using the Bio Edit program.
The classiﬁcation of gene alterations was performed in
accordance with the entries in the Breast Cancer
Information Core (BIC, Bethesda, MD).
Multiplex ligation-dependent probe ampliﬁcation
(MLPA)
The principle of the MLPA technique has been de-
scribed elsewhere [20]. The MLPA test for BRCA1
(P02) and BRCA2 (P45) mutations were obtained
from MRC-Holland, Amsterdam, The Netherlands.
The fragments were analyzed on an ABI model 310
capillary sequencer (Applied Biosystems, Torrence,
CA, USA) using Genescan-TAMRA 500 size stan-
dards (Applied Biosystems). Fragment analysis was
performed with Genescan software.
Results and discussions
We identiﬁed 120 incident Indonesian breast cancer
cases diagnosed before the age of 41 years, or having
family history of breast cancer, or harboring bilateral
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123breast cancer during September 1999–April 2005
(Jogjakarta) and during July 2004–April 2005 (Jakarta
and Denpasar). In addition, 16 of their family members
were analyzed.
The entire coding regions and exon-intron junctions
of BRCA1 and BRCA2 were screened in these 136
persons of breast cancer patients and their families
using PCR-DGGE (Fig. 1) followed by sequencing
(Fig. 2) for samples with aberrant migrating bands. To
optimize the screening, MLPA, a relatively new tech-
nique, was also performed in all samples (Fig. 3). Here,
we report on 116/120 women (96.7%) for whom
BRCA1/2 analysis were completed. The remaining four
patients (all from group A) had to be excluded due to
the small amount of extracted DNA that did not allow
complete screening of the BRCA1 and BRCA2 genes.
BRCA1 and BRCA2 pathogenic mutations
The analysis of 116 unrelated breast cancer patients
with breast cancer revealed that nine patients (7.8%)
carried pathogenic germline mutations especially the
early onset patients: 3 within BRCA1 (2.6%) and 6
within BRCA2 (5.2%) which is comparable to previous
studies [21]. We only found BRCA1 and BRCA2
mutations in groups A (‘‘early onset’’, n = 7 out of 98,
7.1%) and B (two cases of breast cancer in the same
family before the age of 60, n = 2 out of 9 (22.2%))
(Table 1). There were twice as many BRCA2 muta-
tions as BRCA1 mutations. Although the absolute
numbers are low and no ﬁrm conclusions can therefore
be drawn, this is comparable to other Asian regions
[22–24] but seems to discern the Indonesian population
from non-Asian ethnic groups where the reverse trend
is seen.
Seven pathogenic mutations were found in nine
probands: three in BRCA1 (c.2784_2785insT, pL1415X
(c.4361_4362insT), del exon 13–15) and four in BRCA2
(c.3040_3043delGCAA, p.Glu2183X (c.6775G>T),
p.Leu824X (c.2699_2704delTAAATG), p.Gln2894X
(c.9008C>T)). All these mutations were classiﬁed as
pathogenic as they are predicted to result in protein
truncation. The three pathogenic mutations found in
BRCA1 were not previously reported in the BIC
database as well as two novel nonsense mutations
(p.Glu2183X and p.Gln2894X) identiﬁed in BRCA2.
The p.Glu2183X mutation was found in 2 related pa-
tients that had breast cancer above the age of 60.
One of seven pathogenic mutations found in
BRCA1 and BRCA2 showed a signiﬁcant clinical
impact on the patient (Table 2). Patient AE with a
one nucleotide insertion (Thymine) between nucleo-
tide 2784 and 2785 (c.2784_2785insT) in exon 11 of
BRCA1 suffered from bilateral breast cancer at a
relatively early age (25 years). The insertion leads to
frameshift and creates a premature stop codon in exon
11. The mutation takes place in the sequence within
BRCA1 encoding for aminoacids 758–1064 which
interact with RAD51 protein that is required for
homologous recombination (HR) repair of double
strand breaks (DSBs) [25], which is one of the most
important functions of the BRCA1 protein. This pa-
tient presented in a late stage (stage III for both
breasts) and only survived for 9 weeks after treatment.
Her mother did not carry this mutation. Although her
father may be carrier, the mutation is probably de
novo as there was no family history of breast or other
cancers.
The second pathogenic mutation with a signiﬁcant
clinical manifestation was a cytosine for thymine sub-
stitution on nucleotide 9008 of BRCA2 leading to a
premature stop codon in position 2894, c9008C>T
(p.Gln2894X). Patient W presented at age 37 in a late
stage and survived for only 107 weeks after initial
treatment. She had no family history of breast or other
cancers. This mutation lies within exon 21 of BRCA2
which is the proposed site for interaction with the
DSS1 protein that seems to have a fundamental role in
enabling the BRCA2-RAD51 complex to associate
with sites of DNA damage [26].
Fig. 1 DGGE analysis of fragments 11.15 g, 11.4 and 11.10 of
the BRCA2 gene in ten unrelated breast cancer patients. The
arrows show altered band mobility compare to other patients
Breast Cancer Res Treat (2007) 106:297–304 299
123The c.2699_2704delTAAATG (p.Leu824X) in
BRCA2 that has been reported previously by us in the
Indonesian population [17], was found in one other
patient in the present study (Table 1). This mutation
lies in exon 11 BRCA2, within the BRC repeats do-
main. The truncating mutation causes loss of three
quarters of the protein leading to lack of interaction
with the RAD51 protein. Different from BRCA1, the
repair of DSBs by HR is the most important function
of the BRCA2 protein [27]. Patient B-III-5 was diag-
nosed with early stage breast cancer at age 30 with no
family history of breast or other cancers. Her sister
carried the same mutation, but with no present clinical
manifestation as yet. Patient AZ who was diagnosed at
40 years of age, presented in late stage, only survived
46 weeks after initial treatment. This patient also har-
bored a mutation in exon 16 of BRCA1,aGt oA
substitution in nucleotide 5075 (c.5075G>A), which
leads to amino acid change from Methionine to Iso-
leucine, (p.Met16521Ile) which has to date been re-
ported 35 times in BIC as a UV mutation. As the
c.2699_2704delTAAATG mutation was found in two
unrelated patients, this mutation could be a good
candidate as a founder mutation.
None of the families with more than 3 cases of
breast cancer and families with bilateral breast cancer
showed pathogenic mutations in the BRCA1 and
BRCA2 genes. Family U had four ﬁrst-degree relatives
Fig. 2 Sequence
electropherogram of a normal
individual showing (A) wild-
type BRCA2 exon 11





Fig. 3 MLPA analysis of
BRCA1 gene of patient
sample (blue) compare to the
normal control (red). X and Y
axis represent peak size and
peak height respectively.
There are reduced peaks in
the patient sample compared
to the normal control in exons
13, 14 and 15 (arrows)
indicating deletions
300 Breast Cancer Res Treat (2007) 106:297–304
123that were affected by breast cancer. Two of four
members had bilateral breast cancer. In spite of this
high familial breast cancer incidence, no BRCA1/2
mutations were found.
BRCA1 and BRCA2 unclassiﬁed variants
Sixteen (7 BRCA1 and 9 BRCA2) rare mutations of so
far unknown signiﬁcance (‘‘unclassiﬁed variants’’,
Table 1 BRCA1 or BRCA2
germline mutations in
Indonesian women with early
onset breast cancer
a Age at time of diagnosis
b Gen Bank Accession
number, BRCA1: U14680,
BRCA2: U43746
c number of times reported in
BIC
d not determined, detected
by MLPA
Patient Age
a gene Exon Mutation




AE 25 BRCA1 11 c.2784_2785insT frameshift + no
B10 31 BRCA1 13 p.Leu1415X nonsense + no
AA 40 BRCA1 13–15 –
d large rearrangement + no
AB 34 BRCA2 11 c.3040_3043del4 frameshift + 1
B5 66 BRCA2 11 p.Glu2183X nonsense + no
B6 65 BRCA2 11 p.Glu2183X nonsense + no
B-III-5 30 BRCA2 11 p.Leu824X nonsense + no
AZ 40 BRCA2 11 p.Leu824X nonsense + no
W-II 37 BRCA2 21 p.Gln2894X nonsense + no
Q-II 40 BRCA1 2 c.101–10T>C IVS ± 6
P-III-19 19 BRCA1 9 p.Val191Ile Missense ± 6
J22 32 BRCA1 11 p.Leu1209Val Missense ? no
AZ 40 BRCA1 16 p.Met1652Ile Missense ± 35
B1 24 BRCA1 20 c.5313–31A>G IVS ? no
B7 31 BRCA1 24 p.Arg1835Gln Missense ? no
216 33 BRCA1 24 p.Thr1852Ile Missense ? no
P-III-19 19 BRCA2 5 p.Gln147Arg Missense ± 6
B3 24 BRCA2 10 p.Gln609Glu Missense ? no
C-II-7 39 BRCA2 11 p.Met1149Val Missense ± 5
AO 28 BRCA2 11 p.Met1149Val Missense ± 5
AQ 44 BRCA2 11 p.Met1149Val Missense ± 5
BH 38 BRCA2 11 p.Met1149Val Missense ± 5
172 36 BRCA2 11 p.Gln699Leu Missense ? no
J32 29 BRCA2 11 p.Arg2108Cys Missense ± 16
J6 33 BRCA2 11 p.Val950Ile Missense ? no
206 37 BRCA2 25 c.9485–16T>C IVS ± 4
BC 35 BRCA2 27 p.Ile3412Val Missense ± 109
166 33 BRCA2 27 p.Ile3412Val Missense ± 109
J24 35 BRCA2 27 p.Ile3412Val Missense ± 109
206 37 BRCA2 27 p.Lys3326X nonsense ± 289












AE 25 BRCA1 c.2784_2785insT IIIB/IIIA IDC, bilateral pre No DOD 9 w
B10 31 BRCA1 p.Leu1415X I IDC pre No DOD 57 w
AA 40 BRCA1 -
c IIIB IDC N+ pre No AWD
AB 34 BRCA2 c.3040_3043del4 IIIB IDC N+ pre Sister, Int DOD 17 w
B5 63 BRCA2 p.Glu2183X IV Tubular post Sister,Br AWD
B6 65 BRCA2 p.Glu2183X III IDC post Brother, Br AWD
B-III-5 30 BRCA2 p.Leu824X I IDC pre No AWD
AZ 40 BRCA2 p.Leu824X IV IDC pre Sister, Cv DOD 46 w
W-II 37 BRCA2 p.Gln2894X IIIA IDC pre No DOD 107 w
a Age at time of diagnosis
b Gen Bank Accession number, BRCA1: U14680, BRCA2: U43746
c not determined, detected by MLPA
IDC: invasive ductal carcinoma; DOD: dead of disease; bil: bilateral breast cancer; N+: with metastatic to lymph node; Int: intestinum
cancer, Br: breast cancer; Cv: cervical cancer
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123UVs) were detected in 18 patients: 13 missense changes
and 3 intronic variants. Of these 16 UVs, 7 were novel,
whereas the other UVs have been previously reported
in the BIC database (Table 1). From the 18 patients
which carried UV mutations, two patients were de-
tected in families from group D; one patient in a group
B family and the other ﬁfteen patients in families from
group A.
Seven UV were found in the BRCA1 gene, two
mutations occurring in the intronic region between
exons 1 and 2 (c.101–10T>C) and between exons 19
and 20 (c.5313–31A>G), and ﬁve missense mutations
identiﬁed: p.Val191Ile (c.690G>A), p.Leu1209Val
(c.3744T>G), p.Met1652Ile (c.5075G>A), p.Arg1835
Gln (c.5623G>A) and p.Thr1852Ile (c.5674C>T).
Four out of seven BRCA1 missense mutations;
p.Leu1209Val (c.3744T>G), c.5313–31A>G, p.Arg1835
Gln (c.5623G>A) and p.Thr1852Ile (c.5674C>T) were
have not been described previously in the BIC. The
p.Leu1209Val may not be a signiﬁcant change as both
Leucine and Valine belong to the same group of non
polar amino acids. However, p.Arg1835Gln is possibly
an important alteration since a positively charged
Arginine is replaced by an uncharged Glutamine,
which may have an effect on the structure and/or
function of the protein. Another potentially important
alteration concerns p.Thr1852Ile, where the hydro-
philic amino acid Threonine is replaced by a hydro-
phobic Isoleucine. The sites of mutation of both
p.Arg1835Gln and p.Thr1852Ile also have to be con-
sidered as they lie within the site for the activa-
tion domain of the BRCA1 protein [28]. The intronic
UV c.5313–31A>G also deserves further investigation
as it may theoretically have an effect on splicing.
However, according to splice site ﬁnder (http://www.
genet.sickkids.on.ca/~ali/splicesiteﬁnder.html), the
splicing sites in the wild type and mutant alleles are
similar, so therefore we can suggest that the c.5313–
31A>G has no effect on splicing.
Nine different UVs of the BRCA2 gene were found
in fourteen patients (Table1), and three of them were
novel; p.Gln609Glu 9c.2053C>G), p.Gln699Leu
(2324A>T) and p.Val950Ile (3076G>A). One truncat-
ing mutation near the C-terminal end of BRCA2,
p.Lys3326X (c.10204A>T) is probably not pathogenic.
Since the truncating mutation is at the very end of the
protein, it is possible that protein functions are not
affected. Most of the few entries in databanks
describing nonsense mutations near the C terminus of
BRCA2 between codon 3308 and 3408 are described as
UVs. Thus, the effect of this truncating mutation on
cancer predisposition remains unclear.
The p.Val950Ile may not be a signiﬁcant change as
both Valine and Isoleucine belong to the same
group of non polar, hydrophobic amino acids. How-
ever, p Gln609Glu and p.Gln699Leu are potentially
important alterations as for p.Gln609Glu, a non acidic,
polar, hydrophilic Glutamine is replaced by a nega-
tively charged Glutamic acid, whereas for
p.Gln699Leu, an uncharged hydrophilic Glutamine is
replaced by a hydrophobic Leucine. As it takes place
within the BRC repeats of the BRCA2 protein, the p
Gln699Leu alteration might affect protein structure
and function.
To know more about the importance of amino acid
substitutions for protein function, we compared the
amino acid sequence of interest in seven other species,
i.e. Mus musculus, Rattus rattus, Bos taurus, Gallus
gallus, Canis familiaris, Macaca mullata and Mono-
delphis domestica. The missense mutation p.Leu1209-
Val lies in the conserved region of exon 11 of the
BRCA1 gene as the sequence is maintained in seven
other species, whereas p.Arg1835Gln and p.Thr1852Ile
are only conserved in four and three other species
(comparison of p.Arg1835Gln and p.Thr1852Ile with
Bos taurus sequence is not possible because the
BRCA1 gene is shorter). Therefore, even tough the
Leucine to Valine changes may not give any effect
on amino acid charge, its conservation in evolution
is suggestive of a functional role. Interestingly,
p.Gln609Glu and p.Gln699Leu of BRCA2 that result
in a quite dramatic amino acid subtitution that might
lead to protein structure changes, are only conserved in
four and ﬁve species respectively. As for the p.Va-
l950Ile, the conservation in evolution is quite low.
Although p.Gln609Glu is less conserved, we still be-
lieve that Glutamine to Glutamic acid substitution may
have an effect on protein conformation as two adjacent
acidic amino acids will be formed as the result of the
substitution.
Glycosylation moiety of an amino acid also plays a
role in protein function. Amino acid substitutions
involving Serine, Threonine and Asparagine, should
also be checked for their O-GlcNac potential and
threshold. Here we have a Threonine to Isoleucine
substitution (p.Thr1852Ile) that after checking with
YinOYang (http://www.cbs.dtu.dk/services/YinOY-
ang) showed no signiﬁcant threshold changes between
the wildtype and the mutant allele.
The possible effect of amino acid changes in proteins
can also be assessed using similarity scores (based on
Grantham table [29]), in which a value above 100 for
an amino acid substitution indicates a higher chance of
impact on protein function. Among seven novel UVs in
302 Breast Cancer Res Treat (2007) 106:297–304
123the BRCA1 and BRCA2 genes found in the present
study, only p.Gln699Leu in BRCA2 has a similarity
score above 100, whereas p.Gln609Glu and p.Val905Ile
in BRCA2 have the lowest score (Table 3).
Overall, we propose that among the seven novel
UVs, there are three mutations that are possibly
pathogenic: p.Leu1209Val for its location in a con-
served region, and p.Gln609Glu and the p.Gln699Leu
because of two adjacent acidic amino acid being
formed and a high similarity score, respectively.
When comparing the three different Indonesian re-
gions, the percentages of breast cancer patients with
pathogenic BRCA1/2 mutations was signiﬁcantly
higher in Denpasar (Bali island) than in Jogjakarta and
Jakarta (Java island) ((25% (3/12), 7.2% (6/83) and 0%
(0/25) respectively (P = 0.0255, chi-square test)). The
percentages of breast cancer patients with UV muta-
tions in Jakarta, Jogjakarta, and Denpasar were 16%
(4/25), 12% (10/83), and 25% (3/12), respectively (n.s.).
Although the number of patients is too small to draw
ﬁrm conclusions, these data may point to geographic
differences within Indonesia.
It was initially suggested that the BRCA1 and
BRCA2 genes would be responsible for most cases of
inherited breast cancer, but more recent studies sug-
gest that they would account for a far smaller propor-
tion, with considerable variation among different
populations [30]. We found that the incidence of
mutations in these genes varies, depending on the
diagnostic group. In this sense, mutations were present
in (22/102) 21.6% of early onset patients (group A),
28.7% (2/7) in patients with bilateral breast cancer
(group D) and (2/9) 22.2% of patients with two cases of
breast cancer before the age of 60 (group B). The
proportion of families affected by BRCA1/2 mutations
depends on the population analyzed and on the criteria
used to select the patients. Family history of breast
cancer was, however, absent or not suggestive of a
hereditary predisposition in three-fourth of the
deleterious mutations carriers and in more than 90% of
UV carriers. This suggests that BRCA screening poli-
cies based on family history only would miss a con-
siderable proportion of mutation carriers.
In conclusion, a relatively high percentage of early
onset Indonesian breast cancer patients carry a germ-
line mutation in either BRCA1 or BRCA2. Several
novel, pathogenic BRCA1 and BRCA2 germline
mutations have been found, as well as a variety of
novel ‘‘unclassiﬁed variant’’ mutations that may
therefore be speciﬁc for the Indonesian population. It
is likely that some of the ‘‘unclassiﬁed variant’’ muta-
tions may have a functional role in breast cancer
development, which deserves to be explored further.
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